Skip to main content

Table 3 Response rates according to RECIST

From: Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

 

Evaluable patients, n (%)

Responder status

Cohort 1

Cohort 2

 

(n = 9)

(n = 10)

ORR

3 (33)

4 (40)

 CR

0

0b

 PRa

3 (33)

4 (40)

SD ≥7 weeks

3 (33)

3 (30)

 Unconfirmed PRa

1 (11)

2 (20)

PD

3 (33)

3 (30)

  1. ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
  2. aOne patient in cohort 1 and two patients in cohort 2 had unconfirmed partial responses and so were included in the SD seven or more weeks response category.
  3. bFollowing data cut-off, one patient in cohort 2 achieved a CR and, as of December 2012, remained in complete radiological remission; no mutation in the BRCA1 and/or BRCA2 genes was identified in this patient by sequencing and multiplex ligation-dependent probe amplification (MLPA).
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us